• 1. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331
• 2. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
• 3. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 4. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219
• 5. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Aralkylamines
• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Aralkylamines

Methyl(1-Methyl-3-(Trifluoromethyl)-1H-Pyrazol-4-Ylmethyl)Amine Hydrochloride: A Comprehensive Overview

Methyl(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-ylmethyl)amine hydrochloride (CAS No. 1423024-17-2) is a compound of significant interest in the field of medicinal chemistry and pharmaceutical research. This compound, often referred to as MTPA-HCl, has garnered attention due to its unique structural features and potential applications in drug development. This article provides a detailed overview of the compound, including its chemical properties, synthesis methods, biological activities, and recent research advancements.

Chemical Properties and Structure: Methyl(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-ylmethyl)amine hydrochloride is a white crystalline solid with a molecular formula of C₉H₁₂F₃N₃·HCl and a molecular weight of 250.66 g/mol. The compound features a pyrazole ring substituted with a trifluoromethyl group and an N-methylamine moiety, which are key structural elements contributing to its chemical reactivity and biological activity. The presence of the trifluoromethyl group imparts enhanced lipophilicity and metabolic stability, making it an attractive scaffold for drug design.

Synthesis: The synthesis of methyl(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-ylmethyl)amine hydrochloride can be achieved through various routes, but one common method involves the reaction of 1-methyl-3-(trifluoromethyl)-1H-pyrazole-4-carbaldehyde with methylamine in the presence of hydrochloric acid. This reaction typically proceeds via a reductive amination process, where the aldehyde group is reduced to an amine while simultaneously forming the N-methylated product. The final step involves the addition of hydrochloric acid to form the hydrochloride salt.

Biological Activities: Recent studies have highlighted the potential biological activities of methyl(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-ylmethyl)amine hydrochloride. One notable area of research is its activity as a modulator of G protein-coupled receptors (GPCRs). GPCRs are a large family of membrane receptors that play crucial roles in various physiological processes, including neurotransmission, hormone signaling, and immune responses. MTPA-HCl has been shown to exhibit selective agonist or antagonist properties towards specific GPCRs, making it a valuable tool for studying receptor function and developing novel therapeutic agents.

In addition to its GPCR modulating activity, MTPA-HCl has also been investigated for its potential as an anti-inflammatory agent. In vitro studies have demonstrated that the compound can inhibit the production of pro-inflammatory cytokines such as TNF-α and IL-6 in immune cells. This anti-inflammatory effect is attributed to its ability to modulate signaling pathways involved in inflammation, such as NF-κB and MAPK cascades.

Clinical Applications: The unique properties of methyl(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-ylmethyl)amine hydrochloride have led to its evaluation in several preclinical studies for various therapeutic applications. One promising area is its potential use in treating neurological disorders such as Alzheimer's disease and Parkinson's disease. Preclinical studies have shown that MTPA-HCl can improve cognitive function and reduce neuroinflammation in animal models of these diseases.

In the context of cancer research, MTPA-HCl has been studied for its potential as an anticancer agent. In vitro experiments have demonstrated that the compound can induce apoptosis in cancer cells by modulating signaling pathways involved in cell survival and proliferation. These findings suggest that MTPA-HCl may have therapeutic potential in combination with other anticancer drugs.

Current Research Trends: Ongoing research continues to explore new applications and mechanisms of action for methyl(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-ylmethyl)amine hydrochloride. Recent studies have focused on optimizing its pharmacokinetic properties to enhance bioavailability and reduce side effects. For example, researchers are investigating prodrug strategies to improve the oral absorption and stability of MTPA-HCl.

In addition, computational approaches such as molecular docking and virtual screening are being employed to identify novel targets for MTPA-HCl. These methods help predict interactions between the compound and potential protein targets, guiding further experimental validation.

Conclusion: Methyl(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-ylmethyl)amine hydrochloride (CAS No. 1423024-17-2) is a versatile compound with promising applications in medicinal chemistry and pharmaceutical research. Its unique chemical structure confers favorable properties such as lipophilicity and metabolic stability, making it an attractive scaffold for drug design. Recent studies have highlighted its potential as a GPCR modulator, anti-inflammatory agent, and therapeutic candidate for neurological disorders and cancer. As research continues to advance, MTPA-HCl is likely to play an increasingly important role in the development of novel therapeutic agents.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)